The Role of Basiliximab Induction Therapy in Adult-to-Adult Living-Related Transplantation and Deceased Donor Liver Transplantation: A Comparative Retrospective Analysis of a Single-Center Series

J. Viganò, S. Gruttadauria, L. Mandalà, I. Petridis, D. Cintorino, S. Li Petri, G. Varotti, M. Minervini, R. Volpes, D. Biondo, G. Vizzini, W. J. Marsh, A. Marcos, B. Gridelli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: The aim of this study was to report our single-center experience with the use of basiliximab, in combination with a steroid and tacrolimus-based regimen in adult to adult living-related liver transplantation (ALRLT) and in deceased donor liver transplantation (DDLT). Materials and Methods: Seventy-seven consecutive ALRLT recipients (group 1) and 244 DDLT recipients (group 2) were analyzed. All patients received 2 20-mg doses of basiliximab (days 0 and 4 after transplantation) followed by tacrolimus (0.15 mg/kg/d; 10-15 ng/mL target trough levels) and a dose regimen of steroids. Follow-up ranged from 4-1972 days after transplantation in group 1 and from 1-2741 days in group. Results: In group 1, 89.32% of the patients remained rejection-free during follow-up, with an actuarial rejection-free probability of 93.51% within 3 months. Actuarial patient survival rate at 3 years was 84.49%. In group 2, 86.07% of the patients remained rejection-free during follow-up, with an actuarial rejection-free probability of 93.04% within 3 months. Actuarial patient survival rate at 3 years was 87.69%. We observed 14 cases of hepatitis C virus (HCV) recurrence in group 1 (prevalence of 26.92%) and 80 cases in group 2 (prevalence of 54.05%). Conclusion: Basiliximab in association with tacrolimus and steroids is effective in reducing episodes of acute cellular rejection (ACR) and increasing ACR-free survival after ALRLT and DDLT. No difference in patient and graft survival was found between group 1 and 2, nor was there any difference in the incidence of ACR between the 2 groups. However, less risk of HCV recurrence was present in the LRLT group.

Original languageEnglish
Pages (from-to)1953-1955
Number of pages3
JournalTransplantation Proceedings
Volume40
Issue number6
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Liver Transplantation
Transplantation
Tissue Donors
Tacrolimus
Steroids
Hepacivirus
Therapeutics
Survival Rate
Recurrence
Graft Survival
basiliximab
Survival
Incidence

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

The Role of Basiliximab Induction Therapy in Adult-to-Adult Living-Related Transplantation and Deceased Donor Liver Transplantation : A Comparative Retrospective Analysis of a Single-Center Series. / Viganò, J.; Gruttadauria, S.; Mandalà, L.; Petridis, I.; Cintorino, D.; Li Petri, S.; Varotti, G.; Minervini, M.; Volpes, R.; Biondo, D.; Vizzini, G.; Marsh, W. J.; Marcos, A.; Gridelli, B.

In: Transplantation Proceedings, Vol. 40, No. 6, 07.2008, p. 1953-1955.

Research output: Contribution to journalArticle

@article{93ec813a582549269acc9fe094a0f099,
title = "The Role of Basiliximab Induction Therapy in Adult-to-Adult Living-Related Transplantation and Deceased Donor Liver Transplantation: A Comparative Retrospective Analysis of a Single-Center Series",
abstract = "Aim: The aim of this study was to report our single-center experience with the use of basiliximab, in combination with a steroid and tacrolimus-based regimen in adult to adult living-related liver transplantation (ALRLT) and in deceased donor liver transplantation (DDLT). Materials and Methods: Seventy-seven consecutive ALRLT recipients (group 1) and 244 DDLT recipients (group 2) were analyzed. All patients received 2 20-mg doses of basiliximab (days 0 and 4 after transplantation) followed by tacrolimus (0.15 mg/kg/d; 10-15 ng/mL target trough levels) and a dose regimen of steroids. Follow-up ranged from 4-1972 days after transplantation in group 1 and from 1-2741 days in group. Results: In group 1, 89.32{\%} of the patients remained rejection-free during follow-up, with an actuarial rejection-free probability of 93.51{\%} within 3 months. Actuarial patient survival rate at 3 years was 84.49{\%}. In group 2, 86.07{\%} of the patients remained rejection-free during follow-up, with an actuarial rejection-free probability of 93.04{\%} within 3 months. Actuarial patient survival rate at 3 years was 87.69{\%}. We observed 14 cases of hepatitis C virus (HCV) recurrence in group 1 (prevalence of 26.92{\%}) and 80 cases in group 2 (prevalence of 54.05{\%}). Conclusion: Basiliximab in association with tacrolimus and steroids is effective in reducing episodes of acute cellular rejection (ACR) and increasing ACR-free survival after ALRLT and DDLT. No difference in patient and graft survival was found between group 1 and 2, nor was there any difference in the incidence of ACR between the 2 groups. However, less risk of HCV recurrence was present in the LRLT group.",
author = "J. Vigan{\`o} and S. Gruttadauria and L. Mandal{\`a} and I. Petridis and D. Cintorino and {Li Petri}, S. and G. Varotti and M. Minervini and R. Volpes and D. Biondo and G. Vizzini and Marsh, {W. J.} and A. Marcos and B. Gridelli",
year = "2008",
month = "7",
doi = "10.1016/j.transproceed.2008.05.062",
language = "English",
volume = "40",
pages = "1953--1955",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - The Role of Basiliximab Induction Therapy in Adult-to-Adult Living-Related Transplantation and Deceased Donor Liver Transplantation

T2 - A Comparative Retrospective Analysis of a Single-Center Series

AU - Viganò, J.

AU - Gruttadauria, S.

AU - Mandalà, L.

AU - Petridis, I.

AU - Cintorino, D.

AU - Li Petri, S.

AU - Varotti, G.

AU - Minervini, M.

AU - Volpes, R.

AU - Biondo, D.

AU - Vizzini, G.

AU - Marsh, W. J.

AU - Marcos, A.

AU - Gridelli, B.

PY - 2008/7

Y1 - 2008/7

N2 - Aim: The aim of this study was to report our single-center experience with the use of basiliximab, in combination with a steroid and tacrolimus-based regimen in adult to adult living-related liver transplantation (ALRLT) and in deceased donor liver transplantation (DDLT). Materials and Methods: Seventy-seven consecutive ALRLT recipients (group 1) and 244 DDLT recipients (group 2) were analyzed. All patients received 2 20-mg doses of basiliximab (days 0 and 4 after transplantation) followed by tacrolimus (0.15 mg/kg/d; 10-15 ng/mL target trough levels) and a dose regimen of steroids. Follow-up ranged from 4-1972 days after transplantation in group 1 and from 1-2741 days in group. Results: In group 1, 89.32% of the patients remained rejection-free during follow-up, with an actuarial rejection-free probability of 93.51% within 3 months. Actuarial patient survival rate at 3 years was 84.49%. In group 2, 86.07% of the patients remained rejection-free during follow-up, with an actuarial rejection-free probability of 93.04% within 3 months. Actuarial patient survival rate at 3 years was 87.69%. We observed 14 cases of hepatitis C virus (HCV) recurrence in group 1 (prevalence of 26.92%) and 80 cases in group 2 (prevalence of 54.05%). Conclusion: Basiliximab in association with tacrolimus and steroids is effective in reducing episodes of acute cellular rejection (ACR) and increasing ACR-free survival after ALRLT and DDLT. No difference in patient and graft survival was found between group 1 and 2, nor was there any difference in the incidence of ACR between the 2 groups. However, less risk of HCV recurrence was present in the LRLT group.

AB - Aim: The aim of this study was to report our single-center experience with the use of basiliximab, in combination with a steroid and tacrolimus-based regimen in adult to adult living-related liver transplantation (ALRLT) and in deceased donor liver transplantation (DDLT). Materials and Methods: Seventy-seven consecutive ALRLT recipients (group 1) and 244 DDLT recipients (group 2) were analyzed. All patients received 2 20-mg doses of basiliximab (days 0 and 4 after transplantation) followed by tacrolimus (0.15 mg/kg/d; 10-15 ng/mL target trough levels) and a dose regimen of steroids. Follow-up ranged from 4-1972 days after transplantation in group 1 and from 1-2741 days in group. Results: In group 1, 89.32% of the patients remained rejection-free during follow-up, with an actuarial rejection-free probability of 93.51% within 3 months. Actuarial patient survival rate at 3 years was 84.49%. In group 2, 86.07% of the patients remained rejection-free during follow-up, with an actuarial rejection-free probability of 93.04% within 3 months. Actuarial patient survival rate at 3 years was 87.69%. We observed 14 cases of hepatitis C virus (HCV) recurrence in group 1 (prevalence of 26.92%) and 80 cases in group 2 (prevalence of 54.05%). Conclusion: Basiliximab in association with tacrolimus and steroids is effective in reducing episodes of acute cellular rejection (ACR) and increasing ACR-free survival after ALRLT and DDLT. No difference in patient and graft survival was found between group 1 and 2, nor was there any difference in the incidence of ACR between the 2 groups. However, less risk of HCV recurrence was present in the LRLT group.

UR - http://www.scopus.com/inward/record.url?scp=48049089644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049089644&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2008.05.062

DO - 10.1016/j.transproceed.2008.05.062

M3 - Article

C2 - 18675099

AN - SCOPUS:48049089644

VL - 40

SP - 1953

EP - 1955

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 6

ER -